Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Merck in Taiwan
Merck has been active in Taiwan since 1989, and started pharma business in 2006, and acquired Serono to expand into fertility, neurology and endocrinology therapeutic areas. Now, Merck in Taiwan has around 660 employees working in four legal entities and the biopharma business is in under Merck Taiwan Ltd. and is located in Taipei Neihu. To get more information, please visit: www.merck.tw
We help to create, improve and prolong life - continuously working to make a lasting difference in patients' lives. Our portfolio includes medicines to treat cancer, multiple sclerosis, infertility, growth disorders, cardiovascular diseases and diabetes.
We develop high-quality products that protect every member of your family so that they can enjoy healthier, happier lives every day.
A standard treatment in metastatic colorectal cancer as well as carcinoma of the head and neck.
More than two million babies in the world have been born thanks to our fertility treatments.
We help to treat relapsing forms of multiple sclerosis (MS), one of the most common neurological diseases among young adults.
Our products help children and adults with growth hormone deficiencies.
We offer the gold standard for typeⅡdiabetes.
Around 12 million patients per year worldwide are treated with our leading beta blocker.